Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Efficacy Endpoint For BioMarin’s Vimizim Faces FDA Panel Scrutiny

This article was originally published in The Pink Sheet Daily

Executive Summary

Review documents released ahead of a Nov. 19 advisory committee meeting question whether the six-minute walk test is an appropriate endpoint for the Morquio A syndrome treatment, and whether the findings are clinically meaningful.

You may also be interested in...



BioMarin’s Vimizim Secures Broad Label In Morquio A Syndrome

No limits on age or disease severity of patients appear in elosulfase alfa labeling; agency reviewers had raised the issue of baseline function at a November advisory committee meeting.

Vimizim Panel’s Desire For Quality-Of-Life Data Runs Into Regulatory Reality

FDA advisory committee overwhelmingly endorses BioMarin’s elosulfase alfa for Morquio A syndrome based on a walking endpoint but says future studies in the rare disease should include QoL assessments, prompting an agency rep to caution that such instruments need to be fully validated for regulatory purposes.

FDA Panel Backs Efficacy Of BioMarin’s Rare Disease Drug Vimizim

Majority of the Endocrinologic and Metabolic Drugs Advisory Committee says effectiveness of elosulfase alfa has been demonstrated and the drug should be approved for all patients with Morquio A syndrome regardless of baseline disease severity.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel